



CORRECTION

Correction to: Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data

David Chandler · Christine Szekely · Shivani Aggarwal ·

Lori Cyprien · Mark Bensink

Published online: April 4, 2023
© The Author(s) 2023

Correction to: Pain Ther (2021) 10:1551–1566
<https://doi.org/10.1007/s40122-021-00319-z>

In the sentence beginning ‘Healthcare utilization was measured as prescription...’ in this article, the text ‘(service place code 22 [outpatient hospital] or 11 [office])’ should have read ‘(service place code 11 [office])’.

In Table 4 of this article, the data in the row *n* of patients with 2 headed ‘Number of acute medications used, *n* (%)’ was incorrect and it should read as 1144 (25.8) instead of 114 (25.8).

OPEN ACCESS

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0

International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40122-021-00319-z>.

D. Chandler (✉) · M. Bensink
Global Health Economics, Amgen Inc., 1 Amgen
Center Dr, Thousand Oaks, CA 91320, USA
e-mail: the3chandlers@msn.com

C. Szekely · S. Aggarwal · L. Cyprien
Center for Observational Research, Amgen Inc.,
Thousand Oaks, CA, USA